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Genomic analyses identify recurrentMEF2D fusions
in acute lymphoblastic leukaemia
Zhaohui Gu1, Michelle Churchman1, Kathryn Roberts1, Yongjin Li2, Yu Liu2, Richard C. Harvey3, Kelly McCastlain1,
Shalini C. Reshmi4, Debbie Payne-Turner1, Ilaria Iacobucci1, Ying Shao1,2, I-Ming Chen3, Marcus Valentine5, Deqing Pei6,
Karen L. Mungall7, Andrew J. Mungall7, Yussanne Ma7, Richard Moore7, Marco Marra7, Eileen Stonerock8,9,10,
Julie M. Gastier-Foster8,9,10, Meenakshi Devidas11, Yunfeng Dai11, Brent Wood12, Michael Borowitz13, Eric E. Larsen14,
Kelly Maloney15, Leonard A. Mattano Jr16, Anne Angiolillo17, Wanda L. Salzer18, Michael J. Burke19, Francesca Gianni20,
Orietta Spinelli20, Jerald P. Radich21, Mark D. Minden22, Anthony V. Moorman23, Bella Patel24, Adele K. Fielding25,
Jacob M. Rowe26, Selina M. Luger27, Ravi Bhatia28, Ibrahim Aldoss28, Stephen J. Forman29, Jessica Kohlschmidt30,31,
Krzysztof Mro´zek30, Guido Marcucci29, Clara D. Bloomfield30, Wendy Stock32, Steven Kornblau33, Hagop M. Kantarjian33,
Marina Konopleva33, Elisabeth Paietta34, Cheryl L. Willman3, Mignon L. Loh35,36, Stephen P. Hunger37,38 & Charles G. Mullighan1
Chromosomal rearrangements are initiating events in acute lymphoblastic leukaemia (ALL). Here
using RNA sequencing of 560 ALL cases, we identify rearrangements between MEF2D (myocyte
enhancer factor 2D) and five genes (BCL9, CSF1R, DAZAP1, HNRNPUL1 and SS18) in 22 B progenitor
ALL (B-ALL) cases with a distinct gene expression profile, the most common of which is MEF2D-
BCL9. Examination of an extended cohort of 1,164 B-ALL cases identified 30 cases with MEF2D
rearrangements, which include an additional fusion partner, FOXJ2; thus, MEF2D-rearranged cases
comprise 5.3% of cases lacking recurring alterations. MEF2D-rearranged ALL is characterized by a
distinct immunophenotype, DNA copy number alterations at the rearrangement sites, older
diagnosis age and poor outcome. The rearrangements result in enhanced MEF2D transcriptional
activity, lymphoid transformation, activation of HDAC9 expression and sensitive to histone dea-
cetylase inhibitor treatment. Thus, MEF2D-rearranged ALL represents a distinct form of high-risk
leukaemia, for which new therapeutic approaches should be considered.
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B
progenitor acute lymphoblastic leukaemia (B-ALL) is
characterized by recurrent gross chromosomal alterations,
including aneuploidy and rearrangements that deregulate
oncogenes or result in the formation of chimeric fusion proteins
that have functional properties distinct from their non-rearranged
counterparts. Such fusion proteins, including ETV6-RUNX1 and
TCF3-PBX1, and those involving PAX5, KMT2A (MLL) and
tyrosine kinases such as BCR-ABL1, are typically acquired early
in leukaemogenesis and drive tumour formation by perturbing
cellular pathways including haematopoietic development, tumour
suppression, kinase signalling and chromatin remodelling1,2.
Identification of these rearrangements is important in the
management of ALL, as several are associated with treatment
outcome and/or may serve as therapeutic targets.
The prevalence of recurring rearrangements varies significantly
according to age and in part explains the inferior outcome of ALL
in older individuals3,4. For example, rearrangements associated
with favourable outcome such as ETV6-RUNX1 are frequent
in younger children compared with older children, whereas
BCR-ABL1 and rearrangements involving CRLF2 and tyrosine
kinases observed in Philadelphia chromosome-like (Ph-like) ALL
are more common with increasing age3. However, the genetic
basis of up to 30% of ALL cases is unknown.
To identify chromosomal rearrangements in B-ALL cases
lacking a known recurring sentinel alteration, we performed
transcriptome sequencing (RNA sequencing (RNAseq)) of
560 cases and recurrence testing in a cohort of 1,164 cases.
We identified multiple new targets of rearrangement, with
rearrangements of MEF2D and ZNF384 defining subtypes with
distinct transcriptional signatures. In total, a group of 42 cases
are discovered with MEF2D rearranged to BCL9, CSF1R,
DAZAP1 (DAZ (deleted in azoospermia)-associated protein 1),
HNRNPUL1 (heterogeneous nuclear ribonucleoprotein U-like 1),
SS18 (synovial sarcoma translocation, chromosome 18) or FOXJ2
(Forkhead Box J2). These rearrangements dysregulate expression
of MEF2D target genes and, by increasing expression of HDAC9,
create a vulnerability to targeting with histone deacetylase
(HDAC) inhibitors.
Results
RNAseq identifies MEF2D fusions in a novel B-ALL subgroup.
The 560 cases examined by RNAseq enrolled on the Children’s
Oncology Group (COG) trials included AALL0232 (N¼ 216),
AALL0331 (N¼ 65), AALL0932 (N¼ 61), AALL1131 (N¼ 92),
P9906 (N¼ 1) and adults (age of diagnosis Z18, N¼ 122) or
children (age of diagnosis o18, N¼ 3) with B-ALL enroled on
various non-COG protocols (Supplementary Data 1).
This analysis identified multiple new recurring targets of
rearrangement, including MEF2D, NUTM1 and ZNF384, and
new partners of rearrangement with known genes such as PAX5
and IGH (Supplementary Data 1). We identified 22 cases (3.9%)
with rearrangements of MEF2D at chromosome 1q21–22,
encoding myocyte enhancer factor 2D (Table 1, Fig. 1,
Supplementary Data 2 and Supplementary Table 1), representing
15 of 367 (4.1%) childhood cases (up to age 15 years), 4 of 62
(6.5%) adolescent cases (age 16–20 years), 2 of 73 (2.7%) young
adults and a single case in 56 older adults. Five MEF2D fusion
partners were identified: BCL9 (16 cases), HNRNPUL1 (3 cases),
DAZAP1, CSF1R and SS18 (1 case each). Each fusion was
confirmed by reverse transcription and PCR (RT–PCR) followed
by Sanger sequencing (Fig. 1, Supplementary Fig. 1 and
Supplementary Table 2). In each case, the amino terminus of
MEF2D was fused in frame with the carboxy-terminal portion
encoded by the partner gene.
The most common MEF2D rearrangement was MEF2D-BCL9,
which was present in 16 cases. Four isoforms of this fusion were
identified, involving exons 5 or 6 of MEF2D (NM_001271629)
fused in-frame to exons 9 or 10 of BCL9 (NM_004326;
Supplementary Data 2). MEF2D-BCL9 rearrangement was
associated with deregulated expression of the C terminus of
BCL9 distal to the rearrangement breakpoint (Supplementary
Fig. 2). No fusions deregulating expression of full-length BCL9,
such as IGH-BCL9 (ref. 5), were identified. Only one isoform of
the MEF2D-HNRNPUL1 fusion was identified, involving exon 8
of MEF2D and exon 12 of HNRNPUL1. Expression of the
fusion proteins in patient leukaemic cells was confirmed by
immunoblotting (Supplementary Fig. 3) and the disruption of
MEF2D and MEF2D-BCL9 rearrangements were shown to be
present in the majority of leukaemic cells by fluorescence
in situ hybridization (FISH), consistent with the fusions being
leukaemia-initiating events acquired early in leukaemogenesis
(Supplementary Fig. 4). Several patterns of probe hybridization
were identified, consistent with diverse mechanisms of
rearrangement, including insertion of the fusion into a different
chromosome (for example, SJBALL020667), interstitial
insertion at chromosome 1q (SJBALL020703) and reciprocal
rearrangement (SJBALL020987).
Genomic alterations of MEF2D-rearranged cases. MEF2D and
BCL9 are both located at 1q21.2–22 and the common pattern of
interstitial insertion resulted in these rearrangements being
cryptic on cytogenetic analysis. We observed that many
rearrangements were accompanied by copy number alterations at
the MEF2D and partner gene loci. Ten cases harbouring MEF2D
rearrangements had single-nucleotide polymorphism (SNP)
microarray data available (Table 1), with eight of ten exhibiting
focal gains or loss of DNA at the partner genes (MEF2D, BCL9,
DAZAP1 and HNRNPUL1; Supplementary Fig. 5). The genomic
structure of the MEF2D-BCL9 rearrangements was confirmed in
two cases by whole genome sequencing (Supplementary Fig. 6).
Additional genetic alterations identified in MEF2D-rearranged
cases included IKZF1 alterations in three cases, including exons
4–8 deletions in two cases and exons 4–7 deletion in one case
(resulting in the expression of the dominant negative IK6
isoform). Mutational analysis of RNAseq data showed that 6 of
16 MEF2D-BCL9 cases harboured activating NRAS mutations,
although these were frequently subclonal and thus secondary
events in leukaemogenesis (Supplementary Data 1 and
Supplementary Table 3). Analysis of Ras mutations (NRAS,
KRAS, NF1 and PTPN11) across the RNAseq cohort revealed a
similar prevalence of Ras mutations as other subtypes of ALL
previously reported to be enriched for Ras mutations (for
example, hyperdiploid and MLL-rearranged ALL (Supplemen-
tary Fig. 7)).
The transcriptional signatures of MEF2D and ZNF384 ALL.
Although RNAseq data were obtained from diverse library
preparation (total versus messenger RNA, unstranded versus
stranded) and sequencing (75 bp versus 100 bp paired end)
methods, reproducible clustering of MEF2D-rearranged cases was
observed in principal component analysis and hierarchical
clustering (Fig. 2a and Supplementary Figs 8–10), with the
exception of one sample harbouring an MEF2D-CSF1R fusion,
which clustered with Ph-like ALL cases. Rearrangements of
CSF1R, encoding the macrophage colony-stimulating factor
receptor, are observed in Ph-like ALL and result in activation of
tyrosine kinase signalling pathways inhibited by kinase inhibitors
such as imatinib and dasatinib3,6,7. Thus, the clustering of
this sample with other Ph-like ALL cases distinct from other
MEF2D-rearranged cases was not surprising. Supervised analysis
of MEF2D-rearranged cases identified a distinct gene expression
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signature with substantial overlap between cases sequenced using
stranded and unstranded sequencing methods (Fig. 2b and
Supplementary Data 3–5).
Analysis of outlier gene expression in high-risk childhood ALL
previously identified eight ALL subgroups, several of which
harboured recurring genetic alterations including rearrangement
of KMT2A (MLL) (ROSE group 1, R1), TCF3-PBX1 (R2),
deregulation of ERG (R6) and Phþ /Ph-like ALL (R8), and
so on8. Analysis of 1,164 childhood, adolescent and young adult
ALL cases with available microarray gene expression data
identified 31 cases in the R3 subgroup that lacked known
chromosomal rearrangements (Supplementary Fig. 11), 10 of
which were in the discovery RNAseq cohort and had MEF2D
rearrangements (Supplementary Data 1). RT–PCR identified
known MEF2D rearrangements in 19 of the 20 remaining cases
(Supplementary Data 6 and Supplementary Fig. 12). One of the
two remaining cases had sufficient material for RNAseq, which
identified a novel chimeric in-frame fusion of MEF2D exon 8 to
exon 7 of the forkhead transcription factor gene, FOXJ2
(Supplementary Data 6). Taken together, 42 MEF2D-rearranged
cases were discovered in this study that exhibit a distinct gene
expression profile. Moreover, RNAseq identified 20 cases with
rearrangements of ZNF384 to 6 different partners (ARID1B,
CREBBP, EP300, SMARCA2, TAF15 and TCF3), which were also
associated with a distinct gene expression profilez and exclusively
observed in the R5 group (Supplementary Data 7 and
Supplementary Fig. 13). Together, these findings suggest that
MEF2D and ZNF384 rearrangements are founding alterations of
the R3 and R5 subgroups, respectively, and represent distinct
subtypes of B-ALL.
To explore the deregulated gene expression characteristics of
MEF2D-rearranged ALL, we perform the gene set enrichment
analysis (GSEA) and pathway analysis and demonstrated that
MEF2D-rearranged cases exhibited a gene expression profile
of a later maturational stage than other subtypes of ALL
(Supplementary Data 8 and 9). We did observed negative
enrichment of WNT signalling, consistent with the observation
that the MEF2D-BCL9 fusion removes the b-catenin-interacting
domains of BCL9. The clustering of gene expression profiles
MEF2D-rearranged cases irrespective of C-terminal fusion
partner suggests that deregulation of MEF2D function may in
part mediate leukaemogenesis. To examine this, we compared the
Table 1 | Clinical and genetic features of patients with MEF2D-rearranged ALL.
Sample ID Fusion Age WBC Sex Karyotype SNP results
SJBALL013388 MEF2D-BCL9a 10.0 45.4 Female NA NA
SJBALL016252 MEF2D-BCL9a 14.0 42 Female NA NA
SJBALL016291 MEF2D-BCL9a 10.0 23 Male NA NA
SJBALL020667 MEF2D-BCL9a 14.8 39 Female NA No MEF2D change
SJBALL020703 MEF2D-BCL9a 14.2 38 Female 46,XX,del(9)(p22)x2[10]/45,idem, del(9),
þ der(9;17)(q10;q10), 17[6]/46,
idem, del(9),þmar[4]
No MEF2D change
SJBALL020711 MEF2D-BCL9b 13.9 96.4 Male NA Focal gains at MEF2D
and BCL9
SJBALL020906 MEF2D-BCL9b 15.1 9.1 Male NA Deletion between BCL9
and MEF2D
SJCOGALL010235 MEF2D-BCL9a 13.5 82.7 Female 46,XX,dup(1)(q24q31),i(7)(q10),del(9)(p21p24),
add(18)(q21)[8]/46,XX,dup(1)(q24q31),
add(9)(p22),del(9)(p21p24),
del(10)(p13p14)[7]/46,XX[4]
NA
SJBALL014169 MEF2D-BCL9b 21.3 20.9 Female 46,XX,del(12)(p11.2)[2]/45,XX, 9,
del(12)(p11.2)[15] /45,XX, 11[1]
NA
SJBALL020917 MEF2D-HNRNPUL1 11.9 3.5 Female 46,XX,del(13)(q12q32)[24]/46,XX[6] Focal gains at MEF2D and
HNRNPUL1
SJBALL020967 MEF2D-BCL9b 16.3 27 Female 46,X,t(X;6;15)(q22;p21;q13), 2,add(9)(p13),
del(9)(p13p22),der(?)t(?;2)(?;q13)[4]/89,
idemx2, 7, del(9), 11[5]/46,XX[11]
Focal gains at
MEF2D and BCL9
SJBALL020964 MEF2D-HNRNPUL1 17.6 10.8 Male 46,XY,dup(2)(q31q33),del(12)(p11.2)[22] Focal gain at HNRNPUL1
SJBALL016275 MEF2D-BCL9c 15.0 61.9 Male NA NA
SJBALL016306 MEF2D-BCL9c 12.0 61.9 Female NA NA
SJCOGALL010915 MEF2D-BCL9c 14.0 7.4 Male 48,XY,add(3)(q11.2),þ 8,del(8)(p11.1),
add(12)(p11.2),þmar[11]/94,
idemx2,8,8, 21,þmar[6]/46,XY[2]
NA
SJCOGALL010884 MEF2D-BCL9d 13.8 107 Female 46,XX,add(9)(p13)[1]/46,idem,
dup(1)(q12q42)[5]/46,XX[14]
NA
SJBALL020987 MEF2D-BCL9a 18.5 22.5 Female 46,XX,del(9)(p13),t(10;14)(q23;q11.2)[17]/
46,XX[1]
No MEF2D change
SJBALL021005 MEF2D-BCL9a 17.6 9.4 Male NA Deletion at MEF2D,
and adjacent gain to BCL9
SJCOGALL010859 MEF2D-HNRNPUL1 7.6 21.8 Female 46,XX,add(7)(q11.2),add(9)(p13)[8]/46,XX[5] NA
SJBALL016286 MEF2D-SS18 9.0 28.1 Female NA NA
SJBALL020141 MEF2D-DAZAP1* 35.0 5.4 Male NA Gain from MEF2D to 1cent;
Gain from 19p to DAZAP1
SJBALL015117 MEF2D-CSF1Rw 48.0 Female NA NA
NA, not available; SNP, single-nucleotide polymorphism.
Age is shown in years. WBC, peripheral blood leukocyte count at diagnosis, shown as 109/l 1.
Four different isoforms of MEF2D-BCL9 fusions were detected in 16 samples, as denoted by the superscript letters a–d.
*Previously reported26.
wPreviously reported3.
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gene expression profile of MEF2D-rearranged ALL with existing
chromatin immunoprecipitation and sequencing and RNAseq
data sets forMEF2D studies in muscle, retinal and lymphoid cells,
and observed partial overlap with known MEF2D-bound genes.
Notably, HDAC9, one of the top upregulated genes was con-
sistently represented in the data sets (Supplementary Data 10).
HDAC9 is a direct transcriptional target of MEF2 and acts to
inhibit the transcriptional activity of MEF2C9, consistent with the
striking downregulation of this gene in MEF2D-rearranged ALL
(Supplementary Data 3–5 and Supplementary Figs 14 and 15).
Clinical and pathological features of MEF2D ALL. The median
age ofMEF2D-rearranged cases at diagnosis was 14.0 years (range
4.8–48.0) for the 42 MEF2D rearranged cases and 14.0 years
(range 4.8–21.3) for 29 MEF2D-BCL9 cases with approximately
equal occurrence in male and female patients (Supplementary
RNA recognition motif
MEF2D DAZAP1n=1
MEF2D HNRNPUL1n=3
MEF2D SS18n=1
0 100 200 300 400 500 593
3 4 5 221 1,055
Exon 10Exon 6
0 100 200 300 400 500 574
3 4 5 202 1,055
n=1Exon 10Exon 5
0 100 200 300 400 500 600 661
3 4 5 202 968
n=4Exon 9Exon 5
0 100 200 300 400 500 600 680
3 4 5 221 968
n=3Exon 9Exon 6
0 100 200 300 400 500 622
3 4 5 6 7 8 328 563
Exon 8 Exon 12
0 100 200 300 400 500 544
3 4 5 6 7 8 10 118 9328 203
0 100 200 300 400 474
3 4 5 10 11 1268 9221 155
Exon 8 Exon 6
Exon 6 Exon 7
0 100 200 300 400 500 600 714
3 4 5 6 7 13 14 15 16 17 18 19 20 21 22285 543
MEF2D CSF1RExon 7 Exon 11
MADS box domain HJURP_C
AAA domain
PTK catalytic domain
n=1
MEF2D BCL9
0 100 200 300 400
MEF2D
0 200 400 600 800 1,000 1,200 1,426
BCL9
0 100 200 300 407
DAZAP1
0 100 200 300 400 500 600 700 800 900 972
CSF1R
PYGO1 interact region CTNNB1 interact region
SPRY domain
0 100 200 300 400 500 600 700 800 856
HNRNPUL1
0 100 200 300 418
SS18
SSXT protein (N-terminal region)
Ig domain Ig4_SCFR_like
514
n=8
a
b c
L
L
L
L
L
L
L L
N S
S
S
S
A
A A A
A
A A
A
A
N G
G
G
G
A C P
P P P
P P P P P PPCN
NM
S
S
S
S
F S S
S
M M M H
N
NP PPP
PPPP
P P
P
P
P P P P P
S
S
S
S
P V
V
V
V
G
G
G G
G G
G
G G
GG
G G I I
M G I N T
T
T
T
A
A
A
A C
NT Y T
L SF S M PP A A N F T L P D V G D F LNT Y T
Q
QQ
N P R
R
I S
S
A AQ
QQ
S
S
V
V
F F E
EW
ED Q
QQ
FI
I I
T
T
R R
Q Q Q Q
N N
M H HK K K KY R
TCCCCT TCTC T TCCATGCCCACTGCCT ACAACACAGGTCCAATGATGCATCAGCAGCCTCCT TC TCAGCAAT
ACT TCCCAGGCAGGAAAGGGGT T AATGCATCACT TGAAGCCCAAGT ACCAGGTCCGCTGGAAGATCATCGAG
MEF2D HNRNPUL1
MEF2D SS18
MEF2D CSF1R
TCCCCT TC TCT TCCATGCCCACTGCCT ACAACACAGCCAACT TCACGT TGCCAGATGT TGGGGACT TCCTGG
TGAACAGTGCT AACGGAGCCTGCCCCAGCCCTGT TGGT T T TGGAT T T AT T ACT T TCGAGGACGAACAATCAG
MEF2D DAZAP1
TGTCTCCTGGCCTGCCCCAGCGGCCAGCT AGTGCGGGAATGGGCAT T AAT ACACAGAATCCTCGAAT T TCAG
TGAACAGTGCT AACGGAGCCTGCCCCAGCCCTGT TGGAATGGGCAT T AAT ACACAGAATCCTCGAAT T TCAG
TGTCTCCTGGCCTGCCCCAGCGGCCAGCT AGTGCGGGTGGCCCCCCACCTCCT ACAGCCAGCCAGCCTGCCT
TGAACAGTGCT AACGGAGCCTGCCCCAGCCCTGT TGGTGGCCCCCCACCTCCT ACAGCCAGCCAGCCTGCCT
MEF2D BCL9
Figure 1 | MEF2D rearrangements in ALL. (a) Protein structure of wild-type MEF2D and fusion partners, (b) protein structure of each fusion protein and
(c) electropherograms showing the results of RT–PCR and Sanger sequence (see also Supplementary Fig. 1). Four MEF2D-BCL9 isoforms were identified in
16 cases, with breakpoints involving exons 5 or 6 ofMEF2D fused in frame to exons 9 or 10 of BCL9. Rearrangements involvingMEF2D and other four fusion
partners were identified in six samples.MEF2D-DAZAP1 andMEF2D-CSF1R fusions have previously been reported3,26. Protein region annotation: MADS box,
MEF2 (myocyte enhancer factor 2)-like/Type II subfamily of MADS; HJURP_C, Holliday junction regulator protein family C-terminal repeat. Ig domain,
immunoglobulin domain; Ig4_SCFR_like, fourth Ig-like domain of stem cell factor receptor; PTK catalytic domain, tyrosine kinase catalytic domain.
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Figure 2 | MEF2D-rearranged ALL cases have a distinct gene expression profile. (a) Principal component analysis of samples subjected to unstranded
RNAseq data, showing clustering of MEF2D-rearranged cases. A full list of cases and rearrangements identified by RNAseq is provided in Supplementary
Data 1. (b) The gene expression signature for MEF2D-rearranged ALL was determined by comparing 19 MEF2D fusion samples (excluding 2 cases that
failed quality-control threshold for gene expression analysis and one MEF2D-CSF1R rearranged case) and 199 control samples through Wald’s test and
Benjamini–Hochberg adjustment. Genes with adjusted P-value o0.01 are provided in Supplementary Data 3. The top 50 upregulated and top 50
downregulated genes (based on the adjusted P-value) were selected to perform supervised clustering and shown in the order from most significant
upregulated genes (top) to the most downregulated ones (bottom). Stranded-PE100, total stranded paired-end 100bp RNAseq; unstranded-PE100,
unstranded mRNA paired-end 100 bp RNAseq; unstranded-PE75, unstranded mRNA paired-end 75 bp RNAseq. MEF2D, fusions involving MEF2D;
JAK2/TYK2, fusions involving JAK2 or TYK2; PAX5, fusions with PAX5 as the N-terminal fusion partner with non-kinase genes; ABL1/2, fusions with ABL1 or
ABL2 observed in Ph-like ALL; CRLF2, IGH-CRLF2 or P2RY8-CRLF2 fusions; ZNF384, fusions involving ZNF384 as the C-terminal fusion partner; EPOR,
fusions deregulating EPOR observed in Ph-like ALL; PDGFRB, fusions involving PDGFRB; IGH, IGH fusions except IGH-CRLF2 and IGH-EPOR; MLL, fusions
involving KMT2A(MLL) gene.
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Data 1 and 6). The immunophenotype of MEF2D-rearranged
ALL was distinct from other subtypes of B-ALL and was
characterized by weak or absent expression of CD10 and high
expression of CD38. Low or absent expression of CD10 is a
feature of MLL-rearranged ALL and high CD38 expression is
typically seen in normal, regenerating lymphoid cells (haemato-
gones), but these features are otherwise uncommon in B-cell
precursor ALL (Supplementary Table 4).
The outcome ofMEF2D-rearranged ALL was inferior to that of
other ALL subtypes. Although the number of MEF2D-rearranged
cases was small compared with several other subtypes, analysis of
children with ALL enroled on the AALL0232 study of high-risk
pre-B ALL showed that the 5-year event-free survival (EFS) of
MEF2D-rearranged ALL was 71.6% (s.e.±10.2%, n¼ 22),
compared with that of BCR-ABL1 (59.9±8.9%, n¼ 48), MLL
(77.5±10.6%, n¼ 25), Ph-like (60.3±5.5%, n¼ 115) and other
pre-B ALL cases (87.3±1.6%, n¼ 612; log rank test Po0.0001;
Fig. 3). Notably, Ras mutations were not associated with inferior
outcome in this cohort (5 year EFS 89.7±4.2% for 62 cases
with Ras mutations compared with 76.2±4.4% for 112 cases
without, log rank test, P¼NS). Through multivariable analysis
with the Cox proportional-hazards regression model10, MEF2D
rearrangements were not significantly associated with poor
outcome following correction for age (Z10 years unfavourable,
P¼ 0.0034), MRD positivity (Po0.0001), peripheral blood
leukocyte count (Z100mm 3 unfavourable, P¼ 0.0067) and
sex (P¼NS). Further analysis of larger cohorts of MEF2D-
rearranged cases will be required to determine whether this subset
is independently associated with poor outcome.
Deregulation of expression of MEF2D target genes. The
clustering of gene expression profiling data of MEF2D-rearranged
cases with this diverse range of partner genes strongly suggests
the fusions exert similar oncogenic effects. All fusions preserve
the MEF2D MADS-box domain that mediates DNA binding and
potentially dimerization. Thus, aberrant function mediated
by MEF2D transcriptional activation is likely to be central in
leukaemogenesis. To examine this, we performed transcriptional
activation assays in which the ability of MEF2D fusion proteins,
wild-type MEF2D and BCL9, and the rearranged N terminus of
MEF2D to activate transcriptional targets were examined.
This showed that each MEF2D fusion protein was significantly
more potent in activating expression than wild-type MEF2D,
and that truncated MEF2D was inactive (Fig. 4a). Thus, each
fusion partner stabilizes and augments MEF2D transcriptional
activation. In colony-forming assays, MEF2D-BCL9 sustained
serial replating of lymphoid colonies, indicating that this fusion
confers haematopoietic self-renewal (Fig. 4b).
Sensitivity to HDAC inhibition. The poor outcome of
MEF2D-rearranged ALL suggests that new therapeutic
approaches directed against deregulated cellular pathways
observed in this form of leukaemia are warranted. To explore this,
we established xenografts of leukaemic cells of five cases with
MEF2D-rearranged ALL engrafted in immunocompromised
mice. Following engraftment, leukaemic cells were harvested
from the bone marrow and spleen, purified and exposed to
chemotherapeutic agents ex vivo. This demonstrated sensitivity to
the HDAC inhibitor panobinostat (but little sensitivity to BCL9
inhibitors), suggesting HDAC inhibition as a therapeutic option
in this high-risk form of leukaemia (Fig. 4c and Supplementary
Fig. 16a–d). Although HDAC inhibitors such as panobinostat are
broadly active in many haematopoietic tumours, including ALL11
(data for non-MEF2D ALL subtypes are shown in Supplementary
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Figure 3 | Poor outcome of MEF2D-rearranged ALL. The event-free (a,c) and overall survival (b,d) outcome of MEF2D-rearranged cases is compared
with that of B-precursor ALL cases lacking known recurring chromosomal rearrangements (a,b) and key genetic subtypes (c,d) of B-ALL in the COG
AALL0232 study.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13331
6 NATURE COMMUNICATIONS | 7:13331 | DOI: 10.1038/ncomms13331 | www.nature.com/naturecommunications
Fig. 17) and are being explored as a therapeutic option for a range
of relapsed and refractory tumours, we observed exquisite
sensitivity in MEF2D-rearranged ALL (Fig. 4c). In contrast, and
consistent with a lack of activation of b-catenin signalling from
MEF2D-BCL9 fusions, we observed a lack of efficacy of selective,
potent BCL9 inhibitors12 ex vivo (Supplementary Fig. 16e–h).
Discussion
The distinct gene expression profile, tumour cell immunopheno-
type, older age of onset and poor outcome of MEF2D-rearranged
ALL cases together suggest that MEF2D-rearranged ALL
represents a biologically distinct form of leukaemia. The fusion
partners of MEF2D have a diverse range of biological functions.
MEF2D is a member of a family of four myocyte enhancer factor
transcription factors with an important role in neuronal
differentiation13,14. MEF2D is expressed throughout B-cell
differentiation15 and inactivation of Mef2c/d results in an arrest
in B-lymphoid maturation at the pre-B-cell stage15,16. BCL9 is
located on chromosome 1q21 and was first identified as the target
of a t(1;14)(q21;q32) IGH-BCL9 rearrangement in the pre-B-cell
leukaemia cell line CEMO-1 (refs 5,17). Although IGH is
rearranged to a variety of cytokine receptors and transcription
factor genes in ALL, including CRLF2, EPOR and members of the
CEBP family of transcription factors18–21, and multiple known
and novel IGH rearrangements, were identified (Supplementary
Data 1), none of the BCL9 rearrangements identified in this study
involved IGH. BCL9 is a component of the WNT/b-catenin
signalling cascade that has important roles in development, stem
cell self-renewal and oncogenesis. BCL9 is part of the nuclear
complex consisting of T-cell factor/lymphoid enhancer factor,
b-catenin, BCL9/BCL9L and PYGO, which activates transcription
of canonical WNT target genes such as FGF20, DKK1, WISP1,
MYC, CCND1 and GCG (Glucagon)22,23. BCL9 has also been
shown to have an oncogenic role in multiple myeloma24.
The MEF2D-BCL9 rearrangement results in deregulated
expression of the C terminus BCL9 expression (Supplementary
Fig. 2), raising the possibility that these fusions may perturb
WNT/b-catenin signalling. However, the MEF2D-BCL9
rearrangements involve only the last one or two of ten exons of
BCL9 exons resulting in loss of the BCL9 domains that mediate
interaction with PYGO1 and b-catenin, consistent with the lack
of enrichment of WNT/b-catenin signalling in the gene
expression profile of MEF2D-rearranged ALL. Thus, IGH-BCL9
and MEF2D-BCL9 probably exert different roles in leukaemic
transformation. DAZAP1 is located at 19p13.3 and encodes
an RNA-binding protein that interacts with the infertility factors
DAZ and DAZL, and other RNA-binding proteins25. The
MEF2D-DAZAP1 rearrangement has previously been identified
and shown to result in proliferation of fibroblasts26,27.
HNRNPUL1 encodes a nuclear RNA-binding protein of the
heterogeneous nuclear ribonucleoprotein family that may exert a
role in nucleocytoplasmic RNA transport and DNA repair28.
SS18 is fused with SSX1 or SSX2 in synovial sarcoma, and has
putative roles in chromatin remodelling and WNT/b-catenin
signalling29,30. FOXJ2 is a transcription factor that has been
reported to affect migration and invasiveness of various
tumours31,32 but, unlike other forkhead transcription factor
genes, has not previously been identified as a target of
rearrangement in cancer.
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Figure 4 | Luciferase and drug-sensitivity assays. (a) Luciferase assay to test MEF2 binding activities. The average levels of normalized luciferase
activities±s.d. from six replicates are indicated. MEF2D-rearranged isoforms are more potent transcriptional activators than wild-type and truncated MEF2D.
(b). Colony-forming assay for retroviral vectors transduced lineage negative bone marrow cells. Colony number counted from three replicate dishes is shown
in mean±s.d. Western blotting was performed to verify expression of proteins by each construct (Supplementary Fig. 18). RLU, relative luminescence units;
MIG, MSCV-IRES-GFP, represents empty vector; MEF2D-WT, vectors express wild-type MEF2D; MEF2DD, truncated MEF2D; BCL9-WT, wild-type BCL9; M/
B-1 through M/B-3, three most common MEF2D-BCL9 fusion isoforms; M/H, MEF2D-HNRNPUL1. (c) Ex vivo drug sensitivity assays from two xenografted
samples. Four chemical compounds including ABT-199 (selective BCL-2 inhibitor), vincristine and two HDAC inhibitors (panobinostat and vorinostat) were
applied to measure growth inhibition curves in xenografted samples. TheMEF2D rearrangements were confirmed in xenografted samples by RT–PCR and three
more xenografted samples were also tested by the four drugs (Supplementary Fig. 16). Error bars represent mean±s.d.
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These data demonstrate the power of transcriptome sequen-
cing to identify novel rearrangements that define new genetic
subtypes of ALL. The finding of MEF2D rearrangements as a
hallmark of a subtype of ALL with a distinct gene expression
profile provides another example of ALL subtypes that are cryptic
(in this case, due to the common involvement of rearrangement
of two genes co-located on one chromosome) and represented by
rearrangement to diverse partners rather than a single fusion
observed in other subtypes of ALL. Despite the common
involvement of the WNT co-factor BCL9, there was no evidence
of dysregulated WNT/b-catenin signalling in leukaemogenesis. In
contrast, deregulated MEF2D activity, with activation of HDAC9
and resulting inhibition of MEF2C were characteristic of this
form of leukaemia. Further studies are required to dissect the
relative role of MEF2D and partner gene involvement in
leukaemogenesis, but our existing data suggest the potential for
HDAC inhibition in this form of leukaemia.
Methods
Patients and samples. Patients with ALL were enroled on Alliance—Cancer and
Leukemia Group B, COG, City of Hope, Eastern Cooperative Oncology Group,
MD Anderson Cancer Center, Medical Research Council UK, Northern Italian
Leukemia Group, Southwestern Oncology Group and University of Toronto
Protocols (Supplementary Data 1). Patients and/or guardians provided informed
consent/assent. The study was approved by the St. Jude Children’s Research
Hospital Institutional Review Board. Leukaemic cells from bone marrow aspirates
obtained at diagnosis were processed by density gradient centrifugation. Samples of
o70% tumour cell content were purified by fluorescence-activated cell sorting
before RNA extraction.
Transcriptome sequencing and data analysis. Transcriptome sequencing was
performed using TruSeq library preparation and HiSeq 2000 and 2500 sequencers.
All sequencing was paired end and was performed using (1) total RNA and
stranded RNA sequencing (100 bp reads), and (2) polyA-selected mRNA
(100 or 75 bp reads). Sequencing reads were mapped to the GRCh37 human
genome reference by STAR33 (version 2.5.1b) through the two pass mapping
pipeline. Gene annotation downloaded from Ensembl website (http://
www.ensembl.org/) was used for STAR mapping and the following reads count
evaluation. Cicero3 and FusionCatcher34,35 were used to detect fusions.
To assess gene expression profile, reads count for each annotated gene was
extracted by HTSeq package36 and gene expression level normalization and
differential expression analysis was carried out by using DESeq2 bioconductor
R package37. To evaluate the relative gene expression level, regularized
log-transformed (rlog) value was calculated by DESeq2.
Gene expression profile between samples with and without MEF2D fusions
were examined in two ALL cohorts. These included a cohort of total stranded
RNAseq (30-fold coverage on exon regions (D30C)420%) and cases with
unstranded mRNA sequencing (D30C430%). Two MEF2D-rearranged cases
failed to meet the requirement of D30C420% were excluded, both of which were
sequenced by unstranded 75 bp paired end protocol. Two hundred and nineteen
samples were available for gene expression profiling analysis, including 95 samples
with total stranded RNAseq (this cohort was enriched for Ph-like ALL and
included 8 cases with MEF2D fusions) and 124 samples with unstranded RNAseq
(enriched for other B-ALL and included 12 cases with MEF2D fusions) data are
available for the gene expression profiling and gene signature analysis.
GSEA and pathway analysis. Normalized gene expression levels were evaluated
from RNAseq data and subjected to DESeq2 for differential gene expression
analysis. As recommended from GSEA38, genes ranked according to the
significance of differential gene expression levels between samples with and without
target rearrangements and then input to GSEA to calculate potentially enriched
gene sets from a homemade gene sets database. To assess the pathway enrichment,
genes with P-value r0.01 and fold change Z2 were selected to run DAVID
pathway analysis39.
Mutation detection from RNAseq data. The mutations were called according
the GATK40 forum recommended pipeline for calling variant in RNAseq data
(http://gatkforums.broadinstitute.org/gatk/discussion/3891/calling-variants-in-
rnaseq). Specifically, STAR mapped bam files were processed by Picard
(http://broadinstitute.github.io/picard) to mark duplicate reads, then a GATK
module SplitNCigarReads was used to splits reads into exon segments and
hard-clip any sequences overhanging into the intronic regions. Variant calling was
performed by the HaplotypeCaller module in GATK and then the variants were
quality controlled by the following steps: (1) at least three reads support the
mutation and the mutant allele frequency is Z0.05; (2) not observed in common
SNP database (from UCSC version 142); and (3) not observed inZ2 samples from
our germline exome sequence cohort (775 samples). After filtering, all the
mutations were annotated to genes according to their genomic positions.
Non-silent mutations were compared with COSMIC somatic mutation
database (GRCh37-V74) and the overlapped cancer relevant genes
(http://cancer.sanger.ac.uk/census) were kept for further analysis.
Retroviral constructs and immunoblotting. MEF2D-rearranged isoforms,
wild-type MEF2D and BCL9 were amplified by RT–PCR using Phusion
High-Fidelity DNA Polymerase (M0530L, New England Biolabs, Inc.) and primers
(Supplementary Table 5) from either leukaemic cell or MOLT4 cell line
complementary DNA. Amplification products were purified by Wizard SV Gel and
PCR Clean-up system (Promega) and verified by Sanger sequencing. Purified PCR
products were cloned into pCR-Blunt II-TOPO (Life Technologies) and sub-cloned
into the murine stem cell virus-internal ribosome entry site-green fluorescent
protein (MSCV-IRES-GFP) retroviral vector.
Truncated MEF2D isoform was amplified from MSCV-MEF2D-BCL9-IRES-
GFP vector (M/B-1 vector, the one with the most common MEF2D-BCL9 fusion
isoform) by the same PCR system and specially designed primers for Gateway
cloning (Vector NTI, Thermo Fisher) (Supplementary Table 5). Primers for
truncated MEF2D were designed to amplify from the N terminus of MEF2D to the
last amino acid fused to BCL9 with a stop codon inserted at the fusion point.
Purified PCR products were cloned into the Gateway pDONR221 vector (Thermo
Fisher) by BP Clonase Enzyme (Thermo Fisher). Truncated MEF2D-pDONR221
vector was shuttled into a Gateway-compatible MSCV-IRES-GFP vector using the
LR Clonase enzyme (Thermo Fisher). Constructs were verified by Sanger
sequencing (Supplementary Table 5).
Transfected/transduced cells and human leukaemic cells were lysed in RIPA
buffer supplemented with phosphatase inhibitors (Sigma) and 30 mg protein of
patient samples (15 mg of lysate from NIH-3T3 cells) electrophoresed through
4–12% NuPage Bis-Tris gels (Life Technologies) at 190V for 80min. Blots were
probed with anti-MEF2D (H-57, sc-366368), anti-actin (I-19) (both, Santa Cruz
Technologies) and anti-BCL9 (Abcam ab54833). For human leukaemic cells, 1:250,
1:500 and 1:2,000 dilutions were used for MEF2D, BCL9 and b-actin antibodies,
respectively; for transfected/transduced cells, the 3 antibodies were 1:1,000 diluted.
Five percent BSA in Tris-buffered saline with 0.1% Tween 20 solution was used to
dilute the antibodies.
Luciferase assays. In 96-well dishes, 2 104 293T cells were transfected with
0.04 pmols of MSCV-IRES-GFP (MIG) vectors expression wild-type MEF2D,
truncated MEF2D (MEF2DD), wild-type BCL9, three most common
MEF2D-BCL9 fusion isoforms, MEF2D-HNRPULL1 or empty vector along with
250 ng of a 3XMEF2 firefly luciferase reporter construct (Addgene plasmid #32967)
and 50 ng of a pRL-TK Renilla luciferase reporter plasmid (Promega) using FuGene
HD (Roche Diagnostics). Forty-eight hours after transfection, measurement of
firefly and Renilla luciferase activity was performed using the Dual-Glo Luciferase
Assay System (Promega E2920) according to the manufacturer’s instructions. All
transfections were performed with six technical replicates in two independent
experiments. Firefly luciferase activity was normalized according to corresponding
Renilla luciferase activity and reported as TBS-T ±s.d. from one representative
experiment.
Generation of xenografted mice. One million patient-derived leukaemic cells
were transplanted into three mice each by tail vein injection into 8–10-week-old
sublethally irradiated (250 rads) female immunodeficient NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) mice. Disease progression was monitored by flow cytometric
analysis of peripheral blood cells stained for mCD45, hCD45, hCD19 and hCD7,
and the bone marrow and spleen were harvested when 480% of hCD45þ
hCD19þ cells observed in peripheral blood. Mice were housed in an American
Association of Laboratory Animal Care-accredited facility and were treated on
Institutional Animal Care and Use Committee-approved protocols in accordance
with NIH guidelines. The study was approved by institutional review board of St
Jude Children’s Research Hospital.
Ex vivo drug sensitivity assays. Human xenograft cells were flushed from tibiae
and femora of moribund mice, subjected to red cell lysis, washed and immediately
plated 1 105 per well in 96-well plates containing media with the indicated
concentrations of compounds in triplicate. Cells were treated for 48 h, incubated
with resazurin for 4 h and read on a Synergy HT (Biotek).
Colony-forming assays. Bone marrow from 10-week-old C57Bl/6 wild-type mice
was extracted from the tibiae and femora. Red blood cells were lysed and the
remaining bone marrow cells were incubated with a cocktail of biotinylated
anti-mouse antibodies (Gr-1, B220, Ly-1, Ter119, Mac-1, diluted 1:100 in PBS with
5% rat serum and 5% FCS; BD Biosciences) followed by mixing with streptavidin-
coated beads (Dynabeads M-280 Streptavidin; Life Technologies). Cells were
separated on a magnet and unbound cells were collected and incubated at 37 C,
8% CO2 for 2 days in the presence of interleukin (IL)-3, IL-6, stem cell factor
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(SCF), IL-7 and Flt3 cytokines (Peprotech). Cells were retrovirally transduced with
empty MSCV-IRES-GFP (MIG) and MSCV-MEF2D-BCL9-IRES-GFP (M/B-1)
vectors on RetroNectin (Takara Bio) for 48 h before sorting for GFP-positive cells
(BD FACSAria II, BD Biosciences). For clonogenic assays, 10,000 cells were plated
in triplicate in Methocult M3231 (Stem Cell Technologies, Inc.) with the appro-
priate factors (stem cell factor, 100 ngml 1; FLT-3 ligand, 10 ngml 1; IL-7,
20 ngml 1) and colonies were scored 7 days later. For re-plating, 10,000 cells were
cultured in identical conditions, with colonies counted on day 7–10.
FISH analysis. FISH analysis was performed to confirm chromosomal rearran-
gements. As previously described3,41, all assays were performed as sequential
hybridization events first using the 50- and 30-target gene-specific probes in
different colours, to demonstrate the presence or absence of intragenic disruption.
Imaging was performed following the first hybridization and slide coordinates were
recorded. A second hybridization was then performed using the appropriate
50-promoter probe and a second set of images were then made of the previously
imaged cells. To confirm MEF2D-BCL9 rearrangements, sequential probing for
MEF2D and BCL9 was performed using probes prepared from clones RP11-16P22
(MEF2D 50), RP11-959J12 (MEF2D 30) and CH17-105C9 (BCL9 30); to test
IGH-BCL9 fusions, sequential probing for IGH enhancer and BCL9 was carried
out by using probes from RP5-998D24 (IGH enhancer) and CH17-105C9
(BCL9 30).
Statistical analysis. Associations between ALL subtype and treatment outcome
(EFS and overall survival) were performed using the Kaplan–Meier estimator with
Peto’s estimator of s.d. and the log-rank test42–44. Analyses were performed using
Prism v6.0 (GraphPad), R (www.r-project.org)45 and SAS (v9.1.2, SAS Institute,
Cary, NC).
Data availability. Genome and RNAseq data are deposited at the European
Genome Phenome archive, accession EGAS00001000654 (ref. 3),
EGAS00001001952 and the database of Genotypes and Phenotypes (dbGaP) under
accession code phs000463. Data derived from COG samples, including gene
expression and SNP microarray data, may also be accessed through the
Therapeutically Applicable Research to Generate Effective Treatments data matrix
(https://ocg.cancer.gov/programs/target). The remaining data are available within
the article and its Supplementary Files or available from the authors upon request.
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